Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

In the phase III study RESONATE, ibrutinib reduced the risk of progression and improved overall survival versus ofatumumab in previously treated patients with CLL/SLL. In this novel analysis of patient well-being including patient-reported outcomes, ibrutinib reduced disease burden while preserving...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrientos, Jacqueline C., O’Brien, Susan, Brown, Jennifer R., Kay, Neil E., Reddy, Nishitha M., Coutre, Steven, Tam, Constantine, Mulligan, Stephen, Jaeger, Ulrich, Devereux, Stephen, Pocock, Christopher, Robak, Tadeusz, Schuster, Stephen J., Schuh, Anna, Gill, Devinder, Bloor, Adrian, Dearden, Claire, Moreno, Carol, Cull, Gavin, Hamblin, Mike, Jones, Jeffrey A., Eckert, Karl, Solman, Isabelle G., Suzuki, Samuel, Hsu, Emily, James, Danelle F., Byrd, John C., Hillmen, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527106/
https://www.ncbi.nlm.nih.gov/pubmed/30249389
http://dx.doi.org/10.1016/j.clml.2018.08.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527106/
https://www.ncbi.nlm.nih.gov/pubmed/30249389
http://dx.doi.org/10.1016/j.clml.2018.08.007

Ejemplares similares